Author

Ulrike Gerdemann

Boston Children's HospitalORCID 0000-0002-3600-0366Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Ulrike Gerdemann1 paper

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

Francesca Alvarez CalderoniD· 3 shared Marlana Winschel· 3 shared Elisa Rojas PalatoiD· 2 shared Katherine A. MichaelisiD· 2 shared Kayleigh Ingersoll OmdahliD· 2 shared Leslie S. KeaniD· 2 shared Lorenzo S CagniniD· 2 shared Victor TkacheviD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Francesca Alvarez CalderonORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Precision Editing of Cyclophilin A Generates Cyclosporine and Voclosporin Resistant Cellular Therapies

Holly Wobma, Francesca Alvarez Calderon, Jiayi Dong, Kayleigh Ingersoll Omdahl, Xianliang Rui, Elisa Rojas Palato, Rene S. Bermea, Alexandre Albanese, Franziska Wachter, Marlana Winschel, Katherine A. Michaelis, William A. Burns, Gillian Selig, Lorenzo S Cagnin, Victor Tkachev, , Leslie S. Kean

This study edits Cyclophilin A's C-terminus using CRISPR/Cas9 to create cell therapies resistant to cyclosporine and voclosporin, preserving function in immune suppression settings.

Blood Immunology & Cellular Therapy · Apr 20, 2026Peer-reviewedImmunology

PTPN2-KO CAR-T Cells Demonstrate Enhanced Effector Function, CNS Infiltration, and Toxicity in a Non-Human Primate CAR-T Model

Francesca Alvarez Calderon, Ryan A. Fleming, Marlana Winschel, Lev Gorfinkel, Rebecca Sutherland, Katherine A. Michaelis, James Kaminski, Elisa Rojas Palato, Kayleigh Ingersoll Omdahl, Lorenzo S Cagnin, Jennifer F. Lane, Victor Tkachev, Leslie S. Kean, Ulrike Gerdemann

bioRxiv · Sep 17, 2025 · PreprintImmunology

KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma

Nina Weichert‐Leahey, Alla Berezovskaya, Mark W. Zimmerman, Francesca Alvarez Calderon, Marlana Winschel, Silvi Salhotra, Nathaniel W. Mabe, Antonio R. Pérez‐Atayde, Francisca N. de Luna Vitorino, Benjamin Aaron Garcia, Ulrike Gerdemann, Kimberly Stegmaier, Adam David Durbin, Derek A. Oldridge, Brian J. Abraham, Alfred Thomas Look

This study shows that inhibiting KAT6A/B with PF-9363 enhances retinoid efficacy and improves GD2-targeted immunotherapy in neuroblastoma.

bioRxiv · Jul 1, 2025 · PreprintCancer Biology